NDAINHALATIONPOWDER, METERED
Approved
Mar 2019
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Clinical Trials
2
Data completeness
7/8 — Comprehensive
DUAKLIR PRESSAIR (aclidinium bromide and formoterol fumarate) by Azurity is bronchodilators: aclidinium a long-acting muscarinic antagonist (also known as an anticholinergic) and formoterol a long-acting beta 2 -adrenergic agonist. Approved for chronic obstructive pulmonary disease, copd, asthma. First approved in 2019.
Drug data last refreshed 2h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DUAKLIR PRESSAIR is a dual-mechanism inhaled powder combining aclidinium bromide (long-acting muscarinic antagonist) and formoterol fumarate (long-acting beta-2 agonist) for maintenance treatment of COPD and asthma. The combination delivers site-specific bronchodilation through two complementary pathways: anticholinergic M3-receptor blockade and beta-2-mediated smooth muscle relaxation. This dual approach addresses multiple pathophysiological drivers of airflow obstruction in obstructive lung disease.
$0.049MPart D
LOE Approaching2.4 years to LOEProduct is approaching loss of exclusivity (2029) with modest Part D spending ($49K, 70 claims in 2023), indicating niche positioning and a contracted team focus on retention during competitive erosion.
Mechanism of Action
bronchodilators: aclidinium a long-acting muscarinic antagonist (also known as an anticholinergic) and formoterol a long-acting beta 2 -adrenergic agonist. Further information regarding these two substances is provided below. The mechanism of action described below for the individual components…
Worked on DUAKLIR PRESSAIR at Azurity? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.